What makes ZEISS MyoActive different from other myopia management spectacle lenses?

ZEISS MyoActive lenses are the first ZEISS myopia management lenses based on Dynamic Signal Theory . Through ZEISS M.O.V.E. (Micro Optical Variable Elements) technology , the lenses generate dynamic retinal signals by combining multiple levels of myopic defocus with a non-repetitive microstructure layout. This approach is designed to maintain retinal stimulation and support slower axial eye growth.

What clinical evidence supports ZEISS MyoActive lenses?

ZEISS MyoActive lenses have been evaluated in an ongoing randomized controlled clinical trial involving 342 myopic children. After 12 months, ZEISS MyoActive lenses demonstrated the highest efficacy among the tested spectacle lens designs, slowing myopia progression by 0.60 D and axial elongation by 0.22 mm compared with single vision lenses. 1

Which patients are suitable candidates for ZEISS MyoActive lenses?

ZEISS MyoActive lenses are specifically designed for children with myopia and are available in a broad prescription range of up to -9.00 D sphere and 6.00 D cylinder . This makes them suitable for a wide spectrum of pediatric myopia patients who may benefit from an evidence-based myopia management solution.

How quickly do children adapt to ZEISS MyoActive lenses?

Clinical data show excellent wearability and adaptation. 98% of children adapted to ZEISS MyoActive lenses within one week , while 93% rated their distance vision as very good and 93% rated their near vision as good or very good at dispensing. 1,2

How can ZEISS MyoActive be integrated into my myopia management workflow?

ZEISS MyoActive lenses are designed to work within the ZEISS Myopia Management Collective and can be integrated into existing clinical workflows. Eye care professionals can combine the lenses with tools such as ZEISS MYO 200 for biometry, ZEISS MyoConsult for treatment monitoring, and ZEISS VISUFIT 1000 for centration and fitting, helping support a comprehensive myopia management pathway.

ZEISS FOR EYE CARE PROFESSIONALS

ZEISS MyoActive lenses

Our most effective myopia management lens – ever.

Clinical trials confirm: ZEISS MyoActive lenses slow myopia progression by 0.60 D and axial elongation by 0.22 mm. We studied children’s visual behaviour and eye growth, applying these insights to develop ZEISS MyoActive lenses with our patented ZEISS M.O.V.E. technology. The result: MyoActive lenses demonstrate the highest average efficacy in slowing myopia to date.¹

Get in touch

We’re reinventing myopia management.

We developed ZEISS MyoActive lenses based on proven principles and fundamental new insights from recent myopia research. This new approach represents a real breakthrough in myopia management, with ZEISS being the first to translate Dynamic Signal Theory into lens design.

An image of a young boy in class wearing ZEISS MyoActive lenses.

We looked at how kids actually see.

Every day, children see so many visual patterns at different distances and in all kinds of lighting conditions. The demands on their vision are always changing.

A computer-generated image of an eye looking through a myopia management lens, creating myopic defocus on the retina.

Applied simultaneous competing defocus theory.

Research shows that creating myopic defocus triggers a retinal signal in the child’s eye that can slow eye growth – the main cause of myopia progression in children.

A computer-generated image of an eye looking through a ZEISS MyoActive lens, creating dynamic myopic defocus signals on the retina.

Dynamic Signal Theory for lasting impact.

Adding dynamic signals from non-repetitive microstructures to myopic defocus helps retain the retinal response – for effective treatment outcomes that last longer.

Highest average efficacy reported to date.¹

0.60 D

slower myopia progression with ZEISS MyoActive lenses.¹
0.22 mm

reduction in axial elongation thanks to ZEISS MyoActive lenses.¹

Moving the industry with M.O.V.E.^TM technology.

Third-party Content Blocked

The video player is blocked due to your cookie preferences. To change the settings and play the video, please click the button below and consent to use of "Functional" tracking technologies.

ZEISS M.O.V.E. technology in MyoActive lenses

We explored how today visual demands affect refractive development and the effectiveness of myopia treatments. These findings contributed to ZEISS MyoActive: the first lens design to incorporate Dynamic Signal Theory through M.O.V.E.^TM (Micro Optical Variable Elements) technology. We developed ZEISS MyoActive to correct and control myopia in children over the long run.

Computer-generated image of ZEISS MyoActive lenses clearly showing the microstructure layout of the lens.

Microstructures with different positive powers create varying levels of myopic defocus, creating a variety of different retinal signals.

Computer-generated image of a close-up of ZEISS MyoActive lenses showing the different powers in the functional zone.

The non-aligned microstructure layout allows for changing retinal signals as the child’s eye naturally moves across the lens. This helps avoid repetitive stimulation.

Computer-generated image of ZEISS MyoActive lenses showing the non-repetitive layout of microstructures.

The microstructure power ranges and layout pattern enable varying levels of myopic defocus. The resulting dynamic retinal signals help slow axial elongation, sustaining retinal responsiveness.
The result: ZEISS MyoActive is the lens design with the highest average efficacy to date.¹

Computer-generated image of an eye looking through a ZEISS MyoActive lens with dynamic signals triggered at the retina.

Wearing them matters.

Crafted for all-day comfort.

Myopia management lenses make the greatest impact on children’s vision when effective in lens design AND worn throughout the day. And ZEISS MyoActive lens wearers approve:

100% of children show emmetropic-like eye growth.¹
98% of children fully adapt to MyoActive lenses within a week.¹
93% of children claim that their distance vision is very good.^1,2
93% of children rated their near vision as good or very good.^1,2

Manage myopia with Zeiss ZEISS Myopia Management Collective

Other solutions ZEISS MyoCare lens portfolio

Contact Us

Share your inquiry with us

How can we assist you?

Form is loading...

The information entered in the contact form will be used to answer your request by Carl Zeiss Vision International GmbH by E-Mail or phone. Click here to read our statement on data protection.

¹
Two-year prospective, multi-center, double-blind, randomized controlled clinical trial (NCT06563700) by Shanghai Eye Disease Prevention and Treatment Center, China, 2025. Myopic children aged 7-13 years wearing ZEISS MyoActive (N=56) and myopic children aged 7-13 years wearing ZEISS Single Vision Rx lenses (N=56), one-year results as of July 2026, data on file.
²
At dispensing.